This study aims to investigate whether differences in the properties of IAs (such as IA titer, isotypes, avidity, and in vitro neutralizing effects) can be identified in T1D and T2D patients receiving exogenous insulin therapy but exhibiting varying levels of glycemic control. Here, INS is linked to type 1 diabetes mellitus.